Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on KYOWA HAKKO KIRIN CO LTD
11/09 KYOWA HAKKO KIRIN : "Protein Production Method" in Patent Application Approval P..
11/09 KYOWA HAKKO KIRIN : Research Data from Kyowa Hakko Kirin Co Update Understanding..
11/09 KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
11/09 KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
11/06 Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
11/06 KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
11/06 KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
11/03 KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings
11/02 Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
11/01 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently ..
11/01 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
10/31 KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings Company, Limite..
10/30 KYOWA HAKKO KIRIN : Announces Initiation of the Phase III Clinical Study of KHK7..
10/27 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
10/27 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
10/26 KYOWA HAKKO KIRIN : Matters Concerning Voluntary Adoption ofInternational Financ..
10/19 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline for Parkinson's ..
10/17 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline (KW-6002) for Pa..
10/12 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
10/12 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
10/11 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
10/10 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and..
10/10 Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197
10/09 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
10/06 KYOWA HAKKO KIRIN : Announces Discontinuation for Developing ARQ 197 (Tivantinib..
10/05 SYNDAX PHARMACEUTICALS, INC. (NASDAQ : SNDX) Files An 8-K Other Events
10/04 Kyowa Hakko Kirin Co., Ltd. - Notice Concerning Share Transfer Associated wit..
09/29 KYOWA HAKKO KIRIN : Notice Concerning Share Transfer Associated with Change in a..
09/25 Aveo oncology and eusa pharma announce tinivo combination study opt in
09/14 KYOWA HAKKO KIRIN : Researchers Submit Patent Application, "Therapeutic Method a..
09/14 Kyowa Hakko Kirin Co., Ltd. - Ultragenyx and Kyowa Hakko Kirin Announce Addit..
09/14 KYOWA HAKKO KIRIN : Acquired Approval for Additional formulation of ACOALAN® in ..
09/12 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosum..
09/01 Kyowa Hakko Kirin Co., Ltd. - Announcement of submission of supplemental new ..
08/31 KYOWA HAKKO KIRIN CO., LTD. : US Food and Drug Administration Grants Breakthroug..
08/31 ANNOUNCEMENT OF SUBMISSION OF SUPPLE : Hft-290)(123kb)
08/28 KYOWA HAKKO KIRIN CO. LTD. : - US Food and Drug Administration Grants Breakthrou..
08/25 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Burosumab Data Presen..
08/25 Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumabs Biologics ..
08/25 KYOWA HAKKO KIRIN : US Food and Drug Administration Grants Breakthrough Therapy ..
08/25 KYOWA HAKKO KIRIN CO., LTD. :  US Food and Drug Administration Grants Breakthrou..
08/24 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce Submission of Buro..
08/24 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Burosumab Data Presen..
08/17 KYOWA HAKKO KIRIN : Patent Issued for Protein Production Method (USPTO 9725750)
08/11 KYOWA HAKKO KIRIN : Kirin Chooses Verify Brand to Meet Compliance Mandates and G..
07/27 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Regulatory Updates fo..
06/28 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
06/23 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris
06/22 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris(130KB)
06/09 KYOWA HAKKO KIRIN : Pharmaceutical firm boss applauds expansion work
05/25 KYOWA HAKKO KIRIN : Patent Issued for Method of Purifying Protein (USPTO 9650411..
05/22 KYOWA HAKKO KIRIN : FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authorisa..
05/05 KYOWA HAKKO KIRIN : Kirin, Inc. and Dream Foundation Partner to Serve Adults at ..
04/28 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/27 KYOWA HAKKO KIRIN : Researchers Submit Patent Application, "RNAi PHARMACEUTICAL ..
04/27 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/20 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin plan a date with the FDA after..
04/18 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International ..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/07 Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatri..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/06 KYOWA HAKKO KIRIN : "Nucleic Acid That Inhibits Expression of Irf5" in Patent Ap..
04/06 KYOWA HAKKO KIRIN : Investigators from Kyowa Hakko Kirin Co Target Drug Developm..
04/06 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin International Announce Positive D..
03/31 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders(44KB)
03/27 KYOWA HAKKO KIRIN : Announces Top-Line Results of Japanese Phase 3 Clinical Stud..
03/24 KYOWA HAKKO KIRIN : Enters Agreement with AstraZeneca for Development and Commer..
03/23 KYOWA HAKKO KIRIN : Notice regarding allotment of stock acquisition rights (stoc..
03/16 KYOWA HAKKO KIRIN : New Data from Kyowa Hakko Kirin Co Illuminate Findings in Ca..
03/16 KYOWA HAKKO KIRIN : Recent Findings from Kyowa Hakko Kirin Co Provides New Insig..
03/13 Global L-Glutamine (Gln) Market 2017- Kyowa Hakko Kirin, Daesang, Meihua
03/08 The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologic..
03/06 The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologic..
02/20 KYOWA HAKKO KIRIN : Notice regarding the revision of the remuneration system for..
02/20 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
1  2  3Next
Financials ( JPY)
Sales 2017 348 B
EBIT 2017 -
Net income 2017 22 354 M
Finance 2017 23 142 M
Yield 2017 1,16%
P/E ratio 2017 50,16
P/E ratio 2018 45,50
EV / Sales 2017 3,52x
EV / Sales 2018 3,50x
Capitalization 1 248 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 360  JPY
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Masashi Miyamoto Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD33.75%11 130
ABBVIE49.49%149 223
MERCK KGAA-8.66%13 796
JAZZ PHARMACEUTICALS PLC22.78%8 026
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD42.96%6 074
CONVATEC GROUP-12.18%5 289